Transparency of medicinal product pricing and public health insurance

This procedure concerns rules on how member states regulate the prices of medicines and their coverage by public health insurance. It aims to ensure transparency and fair competition within the EU's internal market.

It affects pharmaceutical companies, healthcare providers, and patients by potentially influencing medicine availability and costs. The goal is to harmonize national approaches to drug pricing and reimbursement.